HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

dihydrolenperone

structure given in first source

Also Known As:

RMI 11974; RMI-11974

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Ketones: 2618
  - Butyrophenones: 43
    - dihydrolenperone: 1

Related Diseases

1.	Lung Neoplasms (Lung Cancer) 02/01/1993 - "Phase I trial of dihydrolenperone in lung cancer patients: a novel compound with in vitro activity against lung cancer."
2.	Sleepiness 02/01/1993 - "We conclude: 1) the maximum tolerated dose in our study is 50 mg/square meter orally twice daily, 2) the dose-limiting side effect of dihydrolenperone is somnolence, and 3) the concentrations of dihydrolenperone observed in plasma are significantly lower than those associated with in vitro activity."
3.	Neoplasms (Cancer) 02/01/1993 - "Antitumor activity of the butyrophenone dihydrolenperone in non-small cell lung cancer was initially suggested by in vitro screening against tumor cells derived from fresh surgical samples using the human tumor colony-forming assay. "
4.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/01/1993 - "Antitumor activity of the butyrophenone dihydrolenperone in non-small cell lung cancer was initially suggested by in vitro screening against tumor cells derived from fresh surgical samples using the human tumor colony-forming assay. "